Bioanalytical data is crucial for measuring drug concentrations and is enhanced by thorough analysis and reporting. In clinical trials, such processes help sponsors assess drug safety, make dosing decisions, and secure regulatory approval. CurexBio specializes in providing comprehensive bioanalytical data analysis and reporting support services to convert raw outputs into submission-ready evidence.

What Are Bioanalytical Data Analysis & Reporting Services?

Bioanalytical services focus on the quantitative measurement of drugs, metabolites, and biomarkers in biological matrices like blood and urine. A key aspect is data analysis and reporting, which transforms raw chromatograms and assay results into accurate, compliant documentation for decision-making.

This specialized discipline encompasses:

Bioanalytical Data Analysis and Reporting:

A reliable bioanalytical report is essential for regulators to determine if the concentrations can be trusted for clinical or regulatory decisions. Inadequate data analysis can lead to challenges for sponsors.

Bioanalytical Data Analysis and Reporting

 Accurate analysis and reporting form the essential foundation for regulatory decisions on drug safety and efficacy.

Regulatory Landscape: ICH M10 and the Growing Standards for Reporting

Bioanalytical reporting follows strict guidelines set by ICH M10, established in 2022 and recognized by the FDA. This standard mandates comprehensive documentation of all method validation data and analytical results, encompassing failed runs and out-of-specification quality control tests for regulatory submissions.

Moreover, the guideline demands

Recent FDA guidance highlights that data lacking accuracy, completeness, and attribution may be deemed unreliable for regulatory decisions. Consequently, sponsors face significant risks from using manual data consolidation with spreadsheets, as each copy-paste operation can lead to errors and disrupt data lineage.

CurexBio’s Bioanalytical Data Analysis & Reporting Services:

CurexBio offers bioanalytical data analysis and reporting services that assist sponsors in meeting regulatory requirements. By combining scientific expertise with advanced technologies, they convert raw data into clear, audit-ready reports to streamline submission timelines.

Data Analysis Capabilities

 At CurexBio, we provide comprehensive analytical support throughout all stages of drug development.

  1.     Pharmacokinetic (PK) and Toxicokinetic (TK) Data Analysis: We analyze concentration-time profiles and derive key parameters such as AUC, C_max, T_max, and t½, providing statistically sound results. Our team supports GLP-compliant toxicology studies and clinical trials with precision.
  2.     Bioequivalence (BE) Statistical Analysis: Our rigorous assistance in BE statistical evaluations, utilizing industry-standard tools, compares test and reference formulations to ensure compliance with FDA and international regulatory standards.
  3.     Comprehensive Method Validation Data Analysis: Following ICH M10 and FDA guidelines, critical validation parameters such as selectivity, sensitivity, accuracy, precision, linearity, and stability are analyzed and documented to demonstrate assay performance.
  4.     PK/PD and Integrated Efficacy/Safety Analysis: Our biostatistics team integrates PK exposure data with pharmacodynamic endpoints to offer a comprehensive overview of drug behavior, aiding in the assessment of both efficacy and safety.
  5.     Study Sample Analysis Reports: Complete compilations of analytical run-by-run sample results, including failed runs, reinjections, deviation justifications, and quality control data, are fully documented and audit-ready.
  6.     Clinical Study Reports (CSR): Collaboration with the medical writing team enables the smooth integration of bioanalytical data and conclusions into the final Clinical Study Report (CSR) for global submissions.
  7.     Statistical Analysis Plans (SAP) & TLF Production: We create comprehensive statistical analysis plans and produce tables, listings, and figures (TLFs) to fulfill global regulatory standards.

Our services are built on a foundation of quality and regulatory readiness. CurexBio adheres to ICH E3, ICH E9, and CDISC ADaM/SDTM frameworks, ensuring every deliverable is reproducible, audit‑ready, and structured for seamless integration with your medical writing and data management functions.

Bioanalytical data analysis and reporting serve as essential links between laboratory results and regulatory decisions, impacting patient therapies. With ICH M10 harmonization and stricter FDA expectations for data integrity, sponsors must prioritize reporting. CurexBio provides the necessary expertise and regulatory knowledge for biotech and pharmaceutical companies to convert bioanalytical data into compliant, submission-ready documentation, offering services such as PK data analysis, BE statistical evaluations, method validation reporting, and complete clinical study reporting.

Ready to advance your clinical program with confidence? Contact CurexBio for data analysis and reporting services that can accelerate your journey to regulatory success.